{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T10:57:17Z","timestamp":1769511437726,"version":"3.49.0"},"reference-count":30,"publisher":"Portland Press Ltd.","issue":"5","license":[{"start":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T00:00:00Z","timestamp":1650326400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,5,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The primary objective of this study was to construct an immune-related long noncoding RNAs (IRLs) classifier to precisely predict the prognosis and immunotherapy response of patients with thymic epithelial tumors (TET). Based on univariable Cox regression analysis and Lasso regression, six prognosis-related IRLs (AC004466.3, AC138207.2, AC148477.2, AL450270.1, HOXB-AS1 and SNHG8) were selected to build an IRL classifier. Importantly, results of qRT-PCR validated that higher expression levels of AC138207.2, AC148477.2, AL450270.1 and SNHG8 as well as lower expression levels of AC004466.3, and HOXB-AS1 in TETs samples compared with normal controls. The IRL classifier could effectively classify patients into the low-risk and high-risk groups based on the different survival parameters. In terms of predictive ability and clinical utility, the IRL classifier was superior to Masaoka staging system. Additionally, IRL classifier is significantly associated with immune cells infiltration (dendritic cells, activated CD4 memory T cells and tumor-infiltrating lymphocyte (TIL), T cell subsets in particular), immune microenvironment (immune score and immune checkpoint inhibitors) and immunogenicity (TMB) in TETs, which hints that IRL classifier is tightly correlated with immune characteristics and might guide more effective immunotherapy strategies for TETs patients. Encouragingly, according to TIDE algorithm, there were more immunotherapy responders in the low-risk IRL subgroup and the IRL score was robustly negatively linked to the immunotherapeutic response. To sum up, the IRL classifier was established, which can be used to predict the prognosis, immune infiltration status, immunotherapy response in TETs patients, and may facilitate personalized counseling for immunotherapy.<\/jats:p>","DOI":"10.1042\/bsr20220317","type":"journal-article","created":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T09:06:05Z","timestamp":1650359165000},"update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Construction of immune-related LncRNAs classifier to predict prognosis and immunotherapy response in thymic epithelial tumors"],"prefix":"10.1042","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3630-364X","authenticated-orcid":false,"given":"Yongchao","family":"Su","sequence":"first","affiliation":[{"name":"Department of Thoracic Surgery, Sanya Central Hospital, Sanya, 572000, Hainan Province, PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yangpeng","family":"Ou","sequence":"additional","affiliation":[{"name":"Department of Oncology, Huizhou Third People\u2019s Hospital, Guangzhou Medical University, Huizhou 516000, Guangdong Province, PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongbing","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, the Second Affiliated Hospital of Soochow University, Suzhou 215004, Jiangsu Province, PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ximiao","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Haikou People\u2019s Hospital, Haikou 570208, Hainan Province, PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"288","published-online":{"date-parts":[[2022,5,13]]},"reference":[{"key":"2022051307530973100_B1","doi-asserted-by":"publisher","first-page":"S260","DOI":"10.1097\/JTO.0b013e3181f1f62d","article-title":"Epidemiology of thymoma and associated malignancies","volume":"5","author":"Engels","year":"2010","journal-title":"J. Thorac. Oncol."},{"key":"2022051307530973100_B2","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1097\/JTO.0000000000000663","article-title":"Introduction to the 2015 World Health Organization classification of tumors of the lung, pleura, thymus, and heart","volume":"10","author":"Travis","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"2022051307530973100_B3","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.critrevonc.2016.01.012","article-title":"Thymoma and thymic carcinomas","volume":"99","author":"Scorsetti","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"2022051307530973100_B4","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/ejcts\/ezv239","article-title":"Long-term outcome and prognostic factors of surgically treated thymic carcinoma: results of 306 cases from a Japanese Nationwide Database Study","volume":"49","author":"Hishida","year":"2016","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"2022051307530973100_B5","doi-asserted-by":"publisher","first-page":"7635","DOI":"10.21037\/jtd-2019-thym-12","article-title":"Immunotherapy for thymoma","volume":"12","author":"Jakopovic","year":"2020","journal-title":"J. Thorac. Dis."},{"key":"2022051307530973100_B6","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1186\/s40425-019-0723-9","article-title":"Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma","volume":"7","author":"Rajan","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"2022051307530973100_B7","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ejca.2019.03.012","article-title":"Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study","volume":"113","author":"Katsuya","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"2022051307530973100_B8","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3322\/caac.21596","article-title":"A review of cancer immunotherapy toxicity","volume":"70","author":"Kennedy","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"2022051307530973100_B9","doi-asserted-by":"publisher","first-page":"9180732","DOI":"10.1155\/2020\/9180732","article-title":"15-lncRNA-based classifier-clinicopathologic nomogram improves the prediction of recurrence in patients with hepatocellular carcinoma","volume":"2020","author":"Zhang","year":"2020","journal-title":"Dis. Markers"},{"key":"2022051307530973100_B10","doi-asserted-by":"publisher","first-page":"285","DOI":"10.3389\/fonc.2020.00285","article-title":"Long non-coding RNAs: major regulators of cell stress in cancer","volume":"10","author":"Connerty","year":"2020","journal-title":"Front. Oncol."},{"key":"2022051307530973100_B11","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1089\/dna.2020.5789","article-title":"Development and validation of epigenetic signature predict survival for patients with laryngeal squamous cell carcinoma","volume":"40","author":"Cui","year":"2021","journal-title":"DNA Cell Biol."},{"key":"2022051307530973100_B12","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.it.2017.08.009","article-title":"Control of immune cell homeostasis and function by lncRNAs","volume":"39","author":"Mowel","year":"2018","journal-title":"Trends Immunol."},{"key":"2022051307530973100_B13","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.immuni.2015.05.004","article-title":"Long noncoding RNA in hematopoiesis and immunity","volume":"42","author":"Satpathy","year":"2015","journal-title":"Immunity"},{"key":"2022051307530973100_B14","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1186\/s12935-020-01567-3","article-title":"Identification and validation of methylation-driven genes prognostic signature for recurrence of laryngeal squamous cell carcinoma by integrated bioinformatics analysis","volume":"20","author":"Cui","year":"2020","journal-title":"Cancer Cell Int."},{"key":"2022051307530973100_B15","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s11060-017-2667-6","article-title":"An immune-related lncRNA signature for patients with anaplastic gliomas","volume":"136","author":"Wang","year":"2018","journal-title":"J. Neurooncol."},{"key":"2022051307530973100_B16","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ijsu.2020.03.010","article-title":"Development and validation of nomograms to accurately predict risk of recurrence for patients with laryngeal squamous cell carcinoma: Cohort study","volume":"76","author":"Cui","year":"2020","journal-title":"Int. J. Surg."},{"key":"2022051307530973100_B17","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","article-title":"Robust enumeration of cell subsets from tissue expression profiles","volume":"12","author":"Newman","year":"2015","journal-title":"Nat. Methods"},{"key":"2022051307530973100_B18","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.immuni.2013.10.003","article-title":"Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer","volume":"39","author":"Bindea","year":"2013","journal-title":"Immunity"},{"key":"2022051307530973100_B19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","article-title":"GSVA: gene set variation analysis for microarray and RNA-seq data","volume":"14","author":"H\u00e4nzelmann","year":"2013","journal-title":"BMC Bioinformatics"},{"key":"2022051307530973100_B20","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","article-title":"Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response","volume":"24","author":"Jiang","year":"2018","journal-title":"Nat. Med."},{"key":"2022051307530973100_B21","doi-asserted-by":"publisher","first-page":"5046","DOI":"10.1038\/onc.2014.424","article-title":"A long non-coding RNA links calreticulin-mediated immunogenic cell removal to RB1 transcription","volume":"34","author":"Musahl","year":"2015","journal-title":"Oncogene"},{"key":"2022051307530973100_B22","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ijbiomac.2018.06.033","article-title":"LncRNA SNHG1 regulates the differentiation of Treg cells and affects the immune escape of breast cancer via regulating miR-448\/IDO","volume":"118","author":"Pei","year":"2018","journal-title":"Int. J. Biol. Macromol."},{"key":"2022051307530973100_B23","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41586-021-03626-9","article-title":"TIM-3 restrains anti-tumour immunity by regulating inflammasome activation","volume":"595","author":"Dixon","year":"2021","journal-title":"Nature"},{"key":"2022051307530973100_B24","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.7314\/APJCP.2015.16.7.2851","article-title":"Upregulation and clinicopathological significance of long non-coding NEAT1 RNA in NSCLC tissues","volume":"16","author":"Pan","year":"2015","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"2022051307530973100_B25","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/jcp.29499","article-title":"HOXB-AS1 accelerates the tumorigenesis of glioblastoma via modulation of HOBX2 and HOBX3 at transcriptional and posttranscriptional levels","volume":"236","author":"Bi","year":"2021","journal-title":"J. Cell. Physiol."},{"key":"2022051307530973100_B26","doi-asserted-by":"publisher","first-page":"109000","DOI":"10.1016\/j.biopha.2019.109000","article-title":"Knockdown of SNHG8 repressed the growth, migration, and invasion of colorectal cancer cells by directly sponging with miR-663","volume":"116","author":"Zhen","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"2022051307530973100_B27","doi-asserted-by":"publisher","first-page":"487.e15","DOI":"10.1016\/j.cell.2016.12.022","article-title":"Systemic Immunity is required for effective cancer immunotherapy","volume":"168","author":"Spitzer","year":"2017","journal-title":"Cell"},{"key":"2022051307530973100_B28","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0092-8674(01)00449-4","article-title":"Dendritic cells: specialized and regulated antigen processing machines","volume":"106","author":"Mellman","year":"2001","journal-title":"Cell"},{"key":"2022051307530973100_B29","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1172\/JCI80008","article-title":"Tumor neoantigens: building a framework for personalized cancer immunotherapy","volume":"125","author":"Gubin","year":"2015","journal-title":"J. Clin. Invest."},{"key":"2022051307530973100_B30","doi-asserted-by":"publisher","first-page":"200ra116","DOI":"10.1126\/scitranslmed.3006504","article-title":"Up-regulation of PD-L1, IDO, and T (regs) in the melanoma tumor microenvironment is driven by CD8 (+) T cells","volume":"5","author":"Spranger","year":"2013","journal-title":"Sci. Transl. Med."}],"container-title":["Bioscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20220317\/932814\/bsr-2022-0317.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20220317\/932814\/bsr-2022-0317.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T07:53:50Z","timestamp":1652428430000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/bioscirep\/article\/42\/5\/BSR20220317\/231178\/Construction-of-immune-related-LncRNAs-classifier"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5,27]]}},"URL":"https:\/\/doi.org\/10.1042\/bsr20220317","relation":{},"ISSN":["0144-8463","1573-4935"],"issn-type":[{"value":"0144-8463","type":"print"},{"value":"1573-4935","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,5]]},"published":{"date-parts":[[2022,5]]},"article-number":"BSR20220317"}}